A composition for intranasal delivery of a drug comprising: includes: (i) the drug； and (ii) a non-aqueous vehicle containing (a) propylene glycol and at least one additional solvent selected from N-methylpyrrolidone, propylene carbonate, dimethyl sulfoxide and at least one propylene glycol fatty acid ester； (b) from about 40 to 100% by volume of N-methylpyrrolidone； or (c) from about 40 to 100% by volume of dimethyl sulfoxide (DMSO).
